Assessing the Utility and Safety of Intravenous Iodinated Contrast Media in CT 'Pan Scan' Studies in Geriatric Patients Following Low-Energy Blunt Trauma

评估静脉注射碘造影剂在老年患者低能量钝性创伤后CT“全扫描”检查中的实用性和安全性

阅读:2

Abstract

INTRODUCTION: Ground level falls are common in the geriatric population, often culminating in Emergency Department attendance and a CT 'pan scan'. These scans are routinely performed with intravenous iodinated contrast media (ICM). The types of injuries identified in this cohort can often be adequately characterised without ICM. Safety issues exist with ICM use, with contrast-induced acute kidney injury (CI-AKI) particularly relevant to the geriatric population. This study assessed the diagnostic utility and safety of ICM administration in this cohort. METHODS: A retrospective case control study of geriatric patients undergoing CT pan scan over a 6-month period was performed. Patients were included if they had suffered a ground level fall. The radiology report for each patient was reviewed to assess injury types. The creatinine of each patient who received ICM was assessed to determine the presence of CI-AKI. RESULTS: A total of 549 patients were included in the final analysis. Two hundred four patients suffered at least one traumatic injury. The majority of injuries were musculoskeletal and spinal, with solid organ and vascular injuries only occurring in a small minority. Injuries were more frequently reported on non-contrast studies. 15.4% of patients suffered a CI-AKI. CONCLUSION: Given the types of injuries identified in geriatric patients following low-energy blunt trauma, and when considering CI-AKI and other costs, routine use of ICM on CT pan scans in this population is not necessary. Reserving ICM studies only for patients deemed clinically high risk or with radiologically concerning findings on an initial non-contrast CT is a reasonable compromise.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。